Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Closed Good Friday 04-17 16:00:00 EDT

24.36

-0.04

-0.16%

盘后24.36

+0.000.00%

16:54 EDT

High24.66	Low23.88	Vol43.02K
Open24.58	D1 Closing24.40	Amplitude3.19%
Mkt Cap268.42M	Tradable Cap153.28M	Total Shares11.02M
T/O1.04M	T/O Rate0.68%	Tradable Shares6.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":24.36,"timestamp":1744920000000,"preClose":24.4,"halted":0,"volume":43015,"hourTrading":{"tag":"盘后","latestPrice":24.36,"preClose":24.36,"latestTime":"16:54 EDT","volume":112,"amount":2727.11,"timestamp":1744923293592},"delay":0,"floatShares":6292255,"shares":11018747,"eps":-7.832217,"marketStatus":"Closed Good Friday","change":-0.04,"latestTime":"04-17 16:00:00 EDT","open":24.58,"high":24.66,"low":23.882,"amount":1043780.783605,"amplitude":0.031885,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.832217,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":24.4,"preHourTrading":{"tag":"盘前","latestPrice":25.82,"preClose":24.4,"latestTime":"04:22 EDT","volume":3,"amount":76.26999599999999,"timestamp":1744878126903},"postHourTrading":{"tag":"盘后","latestPrice":24.36,"preClose":24.36,"latestTime":"16:54 EDT","volume":112,"amount":2727.11,"timestamp":1744923293592},"volumeRatio":0.6455645685123925,"impliedVol":0.1122,"impliedVolPercentile":0.1964},"requestUrl":"/m/hq/s/PVLA","defaultTab":"news","newsList":[{"id":"2526650002","title":"Palvella Therapeutics announces data on QTORIN rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2526650002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526650002?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 19:36","pubTimestamp":1744371416,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced QTORIN rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations was featured by...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-data-on-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-data-on-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2526265029","title":"Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2526265029","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526265029?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 19:30","pubTimestamp":1744371000,"startTime":"0","endTime":"0","summary":"Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the des","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060025/0/en/Palvella-Therapeutics-Announces-QTORIN-Rapamycin-3-9-Anhydrous-Gel-for-the-Treatment-of-Microcystic-Lymphatic-Malformations-Featured-in-Oral-Presentation-by-Amy-Paller-M-S-M-D-Chai.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDS","BK4006","BK4139","PVLA","SID","BK4208","BK4213","IEC","NWE","SPD"],"gpt_icon":0},{"id":"2526571183","title":"Director Makes Bold Move with Major Stock Purchase in Palvella Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526571183","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526571183?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 10:02","pubTimestamp":1744336944,"startTime":"0","endTime":"0","summary":"New insider activity at Palvella Therapeutics ( ($PVLA) ) has taken place on April 11, 2025. Director George M. Jenkins has made a significant inve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","MMAT","BK4141","BK4139"],"gpt_icon":0},{"id":"2526352497","title":"Palvella Therapeutics Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352497?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:12","pubTimestamp":1744197120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 07:12 ET (11:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2526735941","title":"Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2526735941","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526735941?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 18:35","pubTimestamp":1744194959,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $49.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2524205040","title":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205040","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205040?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., April 04, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration -approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer ofPalvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT.QTORIN rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-present-jones-healthcare-120000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PVLA","BK4137","HCSG"],"gpt_icon":0},{"id":"2524118947","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118947?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:05 ET (12:05 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2524194968","title":"Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194968?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:56","pubTimestamp":1743504973,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report) today and set a price target of $50.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2524745163","title":"Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524745163","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524745163?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 15:01","pubTimestamp":1743490904,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: $83.6 million as of December 31, 2024.Cash Runway: Expected to extend into the second half of 2027.Research and Development Expenses: $8.2 million for the full-year 2024, compared to $8.8 million in 2023.General and Administrative Expenses: $5.9 million for the full-year 2024, compared to $3.1 million in 2023.Net Loss: $17.4 million or $7.83 per diluted share for the full-year 2024.Net Income : $17.9 million or $2.17 per diluted share for 2023.Projected Cash Spend for 2025: Approximately $30 million.Projected R&D Spend for 2025: $18 million to $20 million.Projected G&A Spend for 2025: $10 million to $12 million.Expected Year-End 2025 Cash Balance: At least $55 million.GuruFocus has detected 3 Warning Signs with ITXXF.Palvella Therapeutics Inc  is leveraging the 505 regulatory pathway for its NDA submission, which could streamline the drug review process and expedite approval.Palvella Therapeutics Inc  reported a net loss of $17.4 million for the full-year 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-inc-pvla-q4-070144507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA"],"gpt_icon":0},{"id":"2523422299","title":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523422299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523422299?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:31","pubTimestamp":1743427908,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryPalvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of $2.72 per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523908945","title":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523908945","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523908945?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:07","pubTimestamp":1743422863,"startTime":"0","endTime":"0","summary":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44559811/correction-palvella-therapeutics-fy24-gaap-eps-7-83-misses-2-10-estimate-cash-balance-of-83-6m-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523198948","title":"Palvella Therapeutics Q4 EPS $(7.83) Misses $(3.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523198948","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523198948?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:36","pubTimestamp":1743421019,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(7.83) per share which missed the analyst consensus estimate of $(3.02) by 159.27 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558839/palvella-therapeutics-q4-eps-7-83-misses-3-02-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523943353","title":"Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523943353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523943353?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:36","pubTimestamp":1743421017,"startTime":"0","endTime":"0","summary":"“2024 was marked by significant progress towards achieving our vision of becoming the leading rare disease biopharmaceutical company focused on ser...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2523194839","title":"Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523194839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523194839?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases. Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN 3.9% rapamycin anhydrous gel  for the treatment of microcystic lymphatic malformations , on track for the first quarter of 2026. Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations , on track for the fourth quarter of 2025. Planned QTORIN pipeline expansion in second half of 2025. Cash and cash equivalents of over $83 million as of December 31, 2024 expected to fund operations into the second half of 2027. Mr. Kaupinen continued, \"In addition to these two initial indications for QTO","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4555","LU1559883803.SGD","BK4585","BK4604","PVLA","TM","03160","LGND","BK4007","LU0566484027.USD","BK4099","BK4588"],"gpt_icon":0},{"id":"2523915166","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915166?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPRO","BK4167","PVH","RDUS","PRGS","ANGO","AYI","PVLA","RANI","SPIR","UNF","NNOX","LU0054578231.USD","BK4023","DARE","AMC","BHST","NCNO","CAG","BK4141","OMER","CELC","GWH","RH","TTGT","FC","PROK","LNN","BK4584","BK4524","BK4178","BK4200","MSM","WPRT","SGML","BW","BK4086","REKR","SLP","APOG","BLRX","LW","PENG","LNZA","CUK","LOAR","BK4007","SPWH","FTCI"],"gpt_icon":0},{"id":"2522537579","title":"Palvella Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537579?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:40","pubTimestamp":1743165606,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to show a fall in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB0XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","PVLA","SDST","CELC","KYTX","PENG","CLSD","SKYH","RANI","FBIO","ADCT","PRGS","LULU","RLMD","FEMY","BRZE","TSAT","AFMD","WGO","ANGO","ATAI","SLRN","CALC","GWH","FTCI","LNZA","MDAI","BHST","EDAP","SPWH","UNCY","IKT","INMB","FC","BW","NCNO","DARE","PVH","WBA","SGML","NUTX","GEVO","GOVX","INR","CRDL","NNOX","TLSI","WKSP","BCAB","REKR"],"gpt_icon":0},{"id":"2522335502","title":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335502?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 01:40","pubTimestamp":1743010809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays,B. Riley, CarMaxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL6N3Q90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","BBIO","CHWY","LU1023059063.AUD","ALNY","SARO","EXEL","LU0054578231.USD","LU0654597011.USD","KMX","RILY","CVX","DLTR","JKS","WING","PVLA","VRT","COTY","HUMA","SG9999002232.USD","ULTA","WVE","GWRS","AEP","SURG","IE00B894F039.SGD","BK4547","LU0980610538.SGD","PSX","LU0823414551.USD","LU0050427557.USD","LU0203345920.USD","SCCO","LU1582987597.SGD","IE00B29SXK94.USD","CTAS","EOG","FCX","BK4127","LU0266512127.USD","COCO","XOM","VVX","LU2506952170.USD","LU0075056555.USD","LU2294711713.HKD","BK4563"],"gpt_icon":1},{"id":"2522385306","title":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2522385306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522385306?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 22:53","pubTimestamp":1743000784,"startTime":"0","endTime":"0","summary":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects** Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O  with \"buy\" rating and $45 PT** New PT re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3PJ1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522876430","title":"Palvella Therapeutics Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2522876430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522876430?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:36","pubTimestamp":1742988960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:36 ET (11:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139","SF","BK4127"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":0.226},{"period":"1month","weight":-0.1256},{"period":"3month","weight":0.8483},{"period":"6month","weight":0.4398},{"period":"1year","weight":0.9383},{"period":"ytd","weight":1.03}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.102904},{"month":2,"riseRate":0.5,"avgChangeRate":0.02179},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.081831},{"month":5,"riseRate":0.555556,"avgChangeRate":0.187589},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.091514},{"month":7,"riseRate":0.7,"avgChangeRate":0.124373},{"month":8,"riseRate":0.6,"avgChangeRate":0.081761},{"month":9,"riseRate":0.3,"avgChangeRate":-0.115283},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082714},{"month":11,"riseRate":0.5,"avgChangeRate":0.04477},{"month":12,"riseRate":0.3,"avgChangeRate":-0.058257}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}